A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Apellis Pharmaceuticals, Inc.167 sites in 1 country792 target enrollmentMarch 4, 2021

ConditionsGeographic Atrophy Secondary to Age-related Macular Degeneration

InterventionsPEGCETACOPLAN (APL-2)

DrugsPEGCETACOPLAN (APL-2)

Overview

Phase: Phase 3
Intervention: PEGCETACOPLAN (APL-2)
Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration
Sponsor: Apellis Pharmaceuticals, Inc.
Enrollment: 792
Locations: 167
Primary Endpoint: Incidence and severity of ocular and systemic adverse events
Status: Completed
Last Updated: 6 months ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or completed the treatment at Month 24 of either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600).

Registry

clinicaltrials.gov

Start Date

March 4, 2021

End Date

September 5, 2025

Last Updated

6 months ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Apellis Pharmaceuticals, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Participants are eligible to be included in the study only if all of the following criteria apply:
•Ocular-specific inclusion criteria apply to the study eye only.
•Subjects must have participated in APL2-103 (NCT03777332) or completed the treatment at Month 24 of either APL2-303 (Derby, NCT03525613) or APL2-304 (Oaks, NCT03525600).
•For subjects who participated in either the 303 or 304 studies, the condition listed below must also be met for participating in this study.
•Subjects who did not fully stop study drug treatment, but missed the visit at Month 24, can also participate in the study. However, to participate, subjects must be seen within 60 days from the last day of the period allowed for the 24 months visit in the previous study.
•The eyes of subjects must have transparency to permit visualization of parts inside the eye such as the retina and subjects must be able to look steadily at a provided target allowing the doctor to get good quality pictures from the eye.
•Female subjects must be:
•Women that cannot have children, or
•Women who can have children must have a negative result of a blood pregnancy test on the first day of the study visit and agree to use ways to avoid pregnancy during the study and 90 days after the last dose of the study medication.
•Males with female partners who can get pregnant must also agree to use ways to avoid pregnancy and agree not to donate sperm while in the study or until 90 days after administering the last dose of the study medication.

Exclusion Criteria

•Subjects cannot take part in the study if the eye that will be treated during the study currently meets any of the following conditions:
•Participants in APL2 303/304 studies who fully stopped study drug treatment before the visit in month 24 but remain in the study to observe the study medication's safety. Those subjects who temporarily paused study drug treatment are still eligible to participate.
•If, according to your doctor you currently have any disease affecting your eyes that could interfere with your vision, including diseases that affect your retina or macula (the center of the back of your eyes). And, if according to your doctor, the disease in your eyes is benign and does not interfere with the study (e.g. diseases that affects the periphery of the retina), you are also eligible to take part in the study.
•If, according to your doctor you currently have any inflammation/infection in or around your eyes that could prohibit you from receiving an injection inside your eyes.
•If, according to your doctor, any current disease that could directly interfere in your participation in the study or that could make it difficult for you to come to the scheduled visits during the next three yearsover the next 36 months.
•If you have known allergies to fluorescein sodium, a solution that is injected into your body for eye testing; or to pegcetacoplan (the study drug) or any inactive substances in pegcetacoplan solution.
•If you currently are pregnant, breastfeed or have a positive pregnancy test.

Arms & Interventions

Pegcetacoplan, 15 mg/100 μL, monthly for up to 36 months

Participants from Study APL2-103 (NCT03777332) or those who completed the treatment at Month 24 from either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600) and were administered monthly intravitreal (IVT) pegcetacoplan (15 mg/100 μL) or monthly sham will receive IVT pegcetacoplan (15 mg/100 μL) monthly for up to approximately 36 months.

Intervention: PEGCETACOPLAN (APL-2)

Pegcetacoplan, 15 mg/100 μL, every other month (EOM) for up to 36 months

Participants from Study APL2-103 (NCT03777332) or those who completed the treatment at Month 24 from either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600) and were administered every other month (EOM) intravitreal (IVT) pegcetacoplan (15 mg/100 μL) or EOM sham will receive IVT pegcetacoplan (15 mg/100 μL) EOM for up to approximately 36 months.

Intervention: PEGCETACOPLAN (APL-2)

Outcomes

Primary Outcomes

Incidence and severity of ocular and systemic adverse events

Time Frame: Up to 36 Months

Secondary Outcomes

Change from baseline in LL-BCVA score (study eye)(Up to 36 Months)
Change from baseline in the total area of GA lesion(s) in the study eye (in mm2)(Up to 36 Months)
Change from baseline in NL-BCVA score (study eye)(Up to 36 Months)